← SynDRA
FILGOTINIB
SynDRA canonical compound SYN0038037 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | JAK2 |
| Mechanism of action | JAK inhibitor |
All known targets
- JAK1
- JAK2
- JAK3
- TYK2
- AAK1
- ADCK1
- BMP2K
- CAMKK2
- CSF1R
- FLT3
- FLT4
- IRAK1
Mechanisms of action (all sources)
- JAK inhibitor
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- TYK2 INHIBITOR
- Tyrosine-protein kinase TYK2 inhibitor
- JAK3 INHIBITOR
- Tyrosine-protein kinase JAK3 inhibitor
- JAK1 MODULATOR
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- filgotinib maleate
- jyseleca
- filgotinib hydrochloride
- G-146034
- G-146034-101
- GLPG-0634
- FILGOTINIB (GLPG0634)
- Filgotinib hydrochloride
- FILGOTINIB??GLPG0643)
- FILGOTINIB(GLPG0643)
- G-146034_101
- G146034
- GLPG0634
- GS-6034 FREE BASE
- Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
- N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
- GLPG 0634
- Filgotinib(GLPG0634)
- Filgotinib (GLPG0634)
- 3XVL385Q0M
- GPLG0634
- N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
- Jyseleca
- Filgotinib [INN]
- N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide.
- Filgotinib [USAN:INN]
- UNII-3XVL385Q0M
- N-(5-{4-[(1,1-Dioxidothiomorpholin-4-Yl)methyl]phenyl}[1,2,4]triazolo[1,5-A]pyridin-2-Yl)cyclopropanecarboxamide
- N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
- Filgotinib (USAN/INN)
- FILGOTINIB [USAN]
- Filgotinib; GPLG0634
- FILGOTINIB [WHO-DD]
- SCHEMBL253559
- Filgotinib pound GLPG0643)
- GTPL7913
- CHEMBL3301607
- AMY3802
Look up FILGOTINIB in the interactive SynDRA portal →